<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00762021</url>
  </required_header>
  <id_info>
    <org_study_id>P-06-26</org_study_id>
    <nct_id>NCT00762021</nct_id>
  </id_info>
  <brief_title>Posterior Capsule Opacification (PCO) Evaluation of the AcrySof SN60AT Lens vs. SN60WF Lens</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess posterior capsule opacification (PCO) in patients implanted with either the AcrySof
      SN60AT lens or the AcrySof SN60WF lens.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Posterior Capsule Opacification (PCO)</measure>
    <time_frame>2 years after surgery</time_frame>
    <description>Thickening and opacification of the transparent membrane on which the intraocular lens is placed assessed by taking a digital retroillumination image of each eye with a dedicated retroillumination camera system. The photographs were analyzed with POCO software to measure the percentage area of PCO in the capsulorhexis area.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>100% LogMAR Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>24 months after surgery</time_frame>
    <description>Best spectacle corrected vision was recorded for each eye of the patients at above follow up visits. The Visual Acuity (VA) measurement was taken under high contrast (100%), which means that there was maximum contrast between the letters on the chart and the background.
VA is measured in logMAR. LogMAR is the &quot;logarithm of the minimum angle of resolution&quot;. A lower logMAR value indicates better visual acuity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>9% LogMAR Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>24 months after surgery</time_frame>
    <description>Best spectacle corrected vision was recorded for each eye of the patients at above follow up visits. The Visual Acuity (VA) measurement was taken under low contrast (9%), which means that there was low contrast between the letters on the chart and the background.
VA is measured in logMAR. LogMAR is the &quot;logarithm of the minimum angle of resolution&quot;. A lower logMAR value indicates better visual acuity.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>SN60AT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation with the AcrySof Intraocular Lens Model SN60AT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SN60WF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Implantation with the AcrySof Intraocular Lens Model SN60WF</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SN60AT</intervention_name>
    <description>Implantation with the AcrySof Intraocular Lens Model SN60AT following cataract removal.</description>
    <arm_group_label>SN60AT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SN60WF</intervention_name>
    <description>Implantation with the AcrySof Intraocular Lens Model SN60WF following cataract removal.</description>
    <arm_group_label>SN60WF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with bilateral senile cataracts

          -  Age &gt; 50 years

          -  Fit for hospital follow ups

          -  Pupils dilating &gt; 6mm preoperatively

          -  Eyes expected to see 6/12 or better postoperatively

        Exclusion Criteria:

          -  Diabetes

          -  On treatment for glaucoma

          -  Other ocular pathology

          -  Previous ocular surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Contact Alcon Call Center for Trial Locations</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2008</study_first_submitted>
  <study_first_submitted_qc>September 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2008</study_first_posted>
  <results_first_submitted>September 30, 2010</results_first_submitted>
  <results_first_submitted_qc>November 24, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 22, 2010</results_first_posted>
  <last_update_submitted>November 24, 2010</last_update_submitted>
  <last_update_submitted_qc>November 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Diane Houtman</name_title>
    <organization>Associate Director, Surgical IOL, Clinical Science</organization>
  </responsible_party>
  <keyword>cataract</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Capsule Opacification</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Uncomplicated age-related bilateral cataract with the potential to see 20/40 or better in each eye</recruitment_details>
      <pre_assignment_details>During the preoperative exam, subjects were examined to ensure they met the inclusion/exclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>SN60AT</title>
          <description>Implantation with the AcrySof Intraocular Lens Model SN60AT</description>
        </group>
        <group group_id="P2">
          <title>SN60WF</title>
          <description>Implantation with the AcrySof Intraocular Lens Model SN60WF</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SN60AT</title>
          <description>Implantation with the AcrySof Intraocular Lens Model SN60AT</description>
        </group>
        <group group_id="B2">
          <title>SN60WF</title>
          <description>Implantation with the AcrySof Intraocular Lens Model SN60WF</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="104"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Posterior Capsule Opacification (PCO)</title>
        <description>Thickening and opacification of the transparent membrane on which the intraocular lens is placed assessed by taking a digital retroillumination image of each eye with a dedicated retroillumination camera system. The photographs were analyzed with POCO software to measure the percentage area of PCO in the capsulorhexis area.</description>
        <time_frame>2 years after surgery</time_frame>
        <population>Data for all patients completing the 24 month visit were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>SN60AT</title>
            <description>Implantation with the AcrySof Intraocular Lens Model SN60AT</description>
          </group>
          <group group_id="O2">
            <title>SN60WF</title>
            <description>Implantation with the AcrySof Intraocular Lens Model SN60WF</description>
          </group>
        </group_list>
        <measure>
          <title>Posterior Capsule Opacification (PCO)</title>
          <description>Thickening and opacification of the transparent membrane on which the intraocular lens is placed assessed by taking a digital retroillumination image of each eye with a dedicated retroillumination camera system. The photographs were analyzed with POCO software to measure the percentage area of PCO in the capsulorhexis area.</description>
          <population>Data for all patients completing the 24 month visit were analyzed.</population>
          <units>Percentage of PCO</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.58" spread="20.18" lower_limit="9.53" upper_limit="31.75"/>
                    <measurement group_id="O2" value="14.04" spread="22.15" lower_limit="11.79" upper_limit="36.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>100% LogMAR Best Corrected Visual Acuity (BCVA)</title>
        <description>Best spectacle corrected vision was recorded for each eye of the patients at above follow up visits. The Visual Acuity (VA) measurement was taken under high contrast (100%), which means that there was maximum contrast between the letters on the chart and the background.
VA is measured in logMAR. LogMAR is the “logarithm of the minimum angle of resolution”. A lower logMAR value indicates better visual acuity.</description>
        <time_frame>24 months after surgery</time_frame>
        <population>Data for all patients completing the 24 month visit were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>SN60AT</title>
            <description>Implantation with the AcrySof Intraocular Lens Model SN60AT</description>
          </group>
          <group group_id="O2">
            <title>SN60WF</title>
            <description>Implantation with the AcrySof Intraocular Lens Model SN60WF</description>
          </group>
        </group_list>
        <measure>
          <title>100% LogMAR Best Corrected Visual Acuity (BCVA)</title>
          <description>Best spectacle corrected vision was recorded for each eye of the patients at above follow up visits. The Visual Acuity (VA) measurement was taken under high contrast (100%), which means that there was maximum contrast between the letters on the chart and the background.
VA is measured in logMAR. LogMAR is the “logarithm of the minimum angle of resolution”. A lower logMAR value indicates better visual acuity.</description>
          <population>Data for all patients completing the 24 month visit were analyzed.</population>
          <units>LogMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.1" lower_limit="0.00" upper_limit="0.08"/>
                    <measurement group_id="O2" value="0.07" spread="0.2" lower_limit="-0.02" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>9% LogMAR Best Corrected Visual Acuity (BCVA)</title>
        <description>Best spectacle corrected vision was recorded for each eye of the patients at above follow up visits. The Visual Acuity (VA) measurement was taken under low contrast (9%), which means that there was low contrast between the letters on the chart and the background.
VA is measured in logMAR. LogMAR is the &quot;logarithm of the minimum angle of resolution&quot;. A lower logMAR value indicates better visual acuity.</description>
        <time_frame>24 months after surgery</time_frame>
        <population>Data for all patients completing the 24 month visit were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>SN60AT</title>
            <description>Implantation with the AcrySof Intraocular Lens Model SN60AT</description>
          </group>
          <group group_id="O2">
            <title>SN60WF</title>
            <description>Implantation with the AcrySof Intraocular Lens Model SN60WF</description>
          </group>
        </group_list>
        <measure>
          <title>9% LogMAR Best Corrected Visual Acuity (BCVA)</title>
          <description>Best spectacle corrected vision was recorded for each eye of the patients at above follow up visits. The Visual Acuity (VA) measurement was taken under low contrast (9%), which means that there was low contrast between the letters on the chart and the background.
VA is measured in logMAR. LogMAR is the &quot;logarithm of the minimum angle of resolution&quot;. A lower logMAR value indicates better visual acuity.</description>
          <population>Data for all patients completing the 24 month visit were analyzed.</population>
          <units>LogMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.2" lower_limit="0.36" upper_limit="0.48"/>
                    <measurement group_id="O2" value="0.45" spread="0.2" lower_limit="0.29" upper_limit="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>SN60AT</title>
          <description>Implantation with the AcrySof Intraocular Lens Model SN60AT</description>
        </group>
        <group group_id="E2">
          <title>SN60WF</title>
          <description>Implantation with the AcrySof Intraocular Lens Model SN60WF</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publications relating to the study should not be made without the Sponsor’s prior written consent and not prior to the completion of the study. The sponsor shall be notified in writing at least 60 days prior to submission of any intention on the part of the Investigator to publish and shall provide the sponsor an opportunity to comment on any proposed publications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alcon Clinical</name_or_title>
      <organization>Alcon Research, Ltd.</organization>
      <phone>888.451.3937; 817.568.6725</phone>
      <email>medinfo@alconlabs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

